Form 4: West Pharmaceutical Services CFO Bernard Birkett Reports Stock Transactions
SEC Form 4 Filing
Bernard Birkett, CFO of West Pharmaceutical Services, reports the acquisition and disposal of common stock and stock options.
Summary
- Bernard Birkett, the Senior Vice President and Chief Financial Officer of West Pharmaceutical Services Inc. (WST), filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
- On February 18, 2025, Birkett acquired 779.353 shares of common stock at a price of $211 per share and disposed of 237.764 shares at the same price.
- He also acquired 124.977 shares and disposed of 35.606 shares at $211.
- Following these transactions, Birkett directly owns 7,520.38 shares of West Pharmaceutical Services Inc.
- Birkett also acquired 4,020 stock options with an exercise price of $211, exercisable beginning February 18, 2026, and expiring February 18, 2035.
- He also acquired 1,740 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Stock option grants and vesting schedules are common compensation practices in the pharmaceutical industry.
- Companies like Amgen, Pfizer, and Johnson & Johnson also utilize stock options and restricted stock units as part of their executive compensation packages.
- The vesting schedule of four equal installments beginning one year after the grant date is a typical arrangement.
Stakeholder Impact
- The filing provides transparency to shareholders regarding the CFO's transactions in the company's stock.
- It can influence investor sentiment depending on the nature and volume of the transactions.
Key Dates
| Date | Description |
|---|---|
| May 16, 2024 | Date of the Limited Power of Attorney execution. |
| February 18, 2025 | Date of the stock transactions and grant of stock options and restricted stock units. |
| February 18, 2026 | First vesting date for the stock options. |
| February 18, 2035 | Expiration date for the stock options. |
| February 20, 2025 | Date of signature for the Form 4 filing. |
Keywords
Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, West Pharmaceutical Services, Bernard Birkett, WST, Securities Exchange Act, CFO, Stock Transactions
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.